Development of a high-content screening assay to identify compounds interfering with the formation of the hepatitis C virus replication complex

Journal of Virological Methods

Volumn 165, Issue 2, 2010, Pages 268-276

  Berke, Jan Martin ^a   Fenistein, Denis ^a   Pauwels, Frederik ^a   Bobbaers, Rob ^a   Lenz, Oliver ^a   Lin, Tse I ^a   Krausz, Eberhard ^a   Fanning, Gregory ^a  

^a TIBOTEC BVBA   (Belgium)

Author keywords

Enhanced green fluorescent protein; Hepatitis C virus; High content screening; Inducible cell line; NS5A; Replication complex

Indexed keywords

2 THENOIC ACID; CILUPREVIR; DOXYCYCLINE; ENHANCED GREEN FLUORESCENT PROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; POLYPROTEIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; CELL LINE; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DRUG IDENTIFICATION; ENDOPLASMIC RETICULUM; FLUORESCENCE MICROSCOPY; GENE INSERTION; HEPATITIS C VIRUS; HIGH CONTENT SCREENING ASSAY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; RNA REPLICATION; SCREENING; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CARRIER PROTEINS; CELL LINE, TUMOR; DOXYCYCLINE; DRUG EVALUATION, PRECLINICAL; ENDOPLASMIC RETICULUM; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HEPACIVIRUS; HUMANS; PROTEASE INHIBITORS; RECOMBINANT FUSION PROTEINS; SMALL MOLECULE LIBRARIES; TRANSFECTION; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 77951023954     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.02.007     Document Type: Article

References (32)

1. Brass V., Bieck E., Montserret R., Wolk B., Hellings J.A., Blum H.E., Penin F., Moradpour D. An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 2002, 277:8130-8139.
2. Chan L., Das S.K., Reddy T.J., Poisson C., Proulx M., Pereira O., Courchesne M., Roy C., Wang W., Siddiqui A., Yannopoulos C.G., Nguyen-Ba N., Labrecque D., Bethell R., Hamel M., Courtemanche-Asselin P., L'Heureux L., David M., Nicolas O., Brunette S., Bilimoria D., Bedard J. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides. Bioorg. Med. Chem. Lett. 2004, 14:793-796.
3. Chan L., Pereira O., Reddy T.J., Das S.K., Poisson C., Courchesne M., Proulx M., Siddiqui A., Yannopoulos C.G., Nguyen-Ba N., Roy C., Nasturica D., Moinet C., Bethell R., Hamel M., L'Heureux L., David M., Nicolas O., Courtemanche-Asselin P., Brunette S., Bilimoria D., Bedard J. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: Tertiary amides. Bioorg. Med. Chem. Lett. 2004, 14:797-800.
4. Duong F.H., Christen V., Berke J.M., Penna S.H., Moradpour D., Heim M.H. Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1. J. Virol. 2005, 79:15342-15350.
5. Egger D., Wolk B., Gosert R., Bianchi L., Blum H.E., Moradpour D., Bienz K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 2002, 76:5974-5984.
6. Faucher A.M., Bailey M.D., Beaulieu P.L., Brochu C., Duceppe J.S., Ferland J.M., Ghiro E., Gorys V., Halmos T., Kawai S.H., Poirier M., Simoneau B., Tsantrizos Y.S., Llinas-Brunet M. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans. Org. Lett. 2004, 6:2901-2904.
7. Flisiak R., Dumont J.M., Crabbe R. Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin. Investig. Drugs 2007, 16:1345-1354.
8. Francois C., Duverlie G., Rebouillat D., Khorsi H., Castelain S., Blum H.E., Gatignol A., Wychowski C., Moradpour D., Meurs E.F. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J. Virol. 2000, 74:5587-5596.
9. Fried M.W., Hadziyannis S.J. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin. Liver Dis. 2004, 24(2):47-54.
10. Gosert R., Egger D., Lohmann V., Bartenschlager R., Blum H.E., Bienz K., Moradpour D. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J. Virol. 2003, 77:5487-5492.
11. Heim M.H., Moradpour D., Blum H.E. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J. Virol. 1999, 73:8469-8475.
12. Hugle T., Fehrmann F., Bieck E., Kohara M., Krausslich H.G., Rice C.M., Blum H.E., Moradpour D. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology 2001, 284:70-81.
13. Ivashkina N., Wolk B., Lohmann V., Bartenschlager R., Blum H.E., Penin F., Moradpour D. The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrane segment. J. Virol. 2002, 76:13088-13093.
14. Ji J., Glaser A., Wernli M., Berke J.M., Moradpour D., Erb P. Suppression of short interfering RNA-mediated gene silencing by the structural proteins of hepatitis C virus. J. Gen. Virol. 2008, 89:2761-2766.
15. Johnson C.L., Owen D.M., Gale M. Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense. J. Biol. Chem. 2007, 282:10792-10803.
16. Liu Z., Yang F., Robotham J.M., Tang H. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J. Virol. 2009, 9:6554-6565.
17. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
18. McCormick C.J., Brown D., Griffin S., Challinor L., Rowlands D.J., Harris M. A link between translation of the hepatitis C virus polyprotein and polymerase function; possible consequences for hyperphosphorylation of NS5A. J. Gen. Virol. 2006, 87:93-102.
19. Moradpour D., Englert C., Wakita T., Wands J.R. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 1996, 222:51-63.
20. Moradpour D., Evans M.J., Gosert R., Yuan Z., Blum H.E., Goff S.P., Lindenbach B.D., Rice C.M. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J. Virol. 2004, 78:7400-7409.
21. Moradpour D., Grabscheid B., Kammer A.R., Schmidtke G., Groettrup M., Blum H.E., Cerny A. Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro. Hepatology 2001, 33:1282-1287.
22. Moradpour D., Kary P., Rice C.M., Blum H.E. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. Hepatology 1998, 28:192-201.
23. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 2007, 5:453-463.
24. Moradpour D., Wakita T., Wands J.R., Blum H.E. Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines. Biochem. Biophys. Res. Commun. 1998, 246:920-924.
25. Piccoli C., Scrima R., Quarato G., D'Aprile A., Ripoli M., Lecce L., Boffoli D., Moradpour D., Capitanio N. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology 2007, 46:58-65.
26. Polyak S.J., Paschal D.M., McArdle S., Gale M.J., Moradpour D., Gretch D.R. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999, 29:1262-1271.
27. Schmidt-Mende J., Bieck E., Hugle T., Penin F., Rice C.M., Blum H.E., Moradpour D. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 2001, 276:44052-44063.
28. Soriano V., Madejon A., Vispo E., Labarga P., Garcia-Samaniego J., Martin-Carbonero L., Sheldon J., Bottecchia M., Tuma P., Barreiro P. Emerging drugs for hepatitis C. Expert Opin. Emerg. Drugs 2008, 13:1-19.
29. Stauber R.E., Kessler H.H. Drugs in development for hepatitis C. Drugs 2008, 68:1347-1359.
30. Targett-Adams P., McLauchlan J. Development and characterization of a transient-replication assay for the genotype 2a hepatitis C virus subgenomic replicon. J. Gen. Virol. 2005, 86:3075-3080.
31. Wolk B., Buchele B., Moradpour D., Rice C.M. A dynamic view of hepatitis C virus replication complexes. J. Virol. 2008, 82:10519-10531.
32. Wolk B., Sansonno D., Krausslich H.G., Dammacco F., Rice C.M., Blum H.E., Moradpour D. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J. Virol. 2000, 74:2293-2304.